Vanda Q2 2026 Earnings: Fanapt Growth Could Not Prevent a Wider Loss

Vanda Pharmaceuticals (Nasdaq: VNDA) reported Q2 2026 revenue of $50.5 million, down 4% from $52.6 million a year earlier, while GAAP diluted loss per share widened to $1.04 from $0.46. Fanapt sales grew 23%, but that increase was outweighed by lower HETLIOZ revenue and substantially higher spending on product launches and clinical programs. Cash and marketable securities ended the quarter at $170.0 million.

Core financial results

The deterioration in profitability was considerably larger than the decline in revenue. Total operating expenses rose 25.5% to $114.3 million, including a 68% increase in research and development spending and an 11% increase in selling, general and administrative expenses.

Vanda attributed the higher spending to Phase III programs, continued commercialization of existing products, and preparations and manufacturing for the launches of NEREUS, BYSANTI and Quimilza.

The net loss increased more sharply than the pretax loss partly because Q2 2025 included a $7.7 million income tax benefit, compared with a $0.1 million tax provision in Q2 2026.

Product performance

Fanapt remained Vanda’s largest product and the main source of growth. Its total prescriptions increased 31% and new-to-brand prescriptions rose 32%, supporting a 23% increase in sales. PONVORY also grew, while the early NEREUS launch generated its first $1.0 million of quarterly revenue.

HETLIOZ was the primary drag on reported revenue. Its Q2 sales excluded approximately $7.0 million of orders shipped on June 29 but delivered on July 1; Vanda expects to recognize those orders in Q3 2026.

NEREUS became commercially available through a direct-to-consumer web offering in May 2026. Vanda expects personal promotion to begin later in the year. BYSANTI, approved in Q1 2026 for bipolar I disorder and schizophrenia, is scheduled for launch in the second half of 2026.

Launch and pipeline spending widened losses despite Fanapt growth

The central issue in the quarter was the gap between product momentum and the cost of building Vanda’s commercial and clinical pipeline. Fanapt added approximately $6.7 million of revenue from the prior-year period, but total revenue still declined as reported HETLIOZ sales fell by approximately $10.6 million. At the same time, research and development expenses increased by about $15.0 million and SG&A expenses rose by about $7.2 million.

Cash, cash equivalents and marketable securities declined by $32.3 million during Q2 and by $93.8 million during the first six months of 2026, ending June at $170.0 million. Management expects operating expenses to begin moderating later in 2026 and to decrease more substantially during 2027. Based on current cash and anticipated product revenue, Vanda expects to have sufficient resources to fund operations through at least the end of 2027.

2026 guidance

Vanda reiterated its full-year 2026 total revenue guidance of $240 million to $290 million. The product-level outlook now combines Fanapt and BYSANTI based on the expected timing of the BYSANTI launch.

With first-half revenue of $102.2 million, the full-year range implies approximately $137.8 million to $187.8 million of revenue in the second half. Execution of the BYSANTI and NEREUS launches, together with the Q3 recognition of the delayed HETLIOZ orders, will therefore be important to the full-year outcome.

Upcoming commercial and clinical milestones

Vanda has several regulatory and Phase III events scheduled through the end of 2026 and early 2027. These milestones could affect both future product opportunities and the company’s spending requirements.

Recent insider transactions

The supplied six-month insider summary reports 1,437,537 shares acquired across 14 purchase transactions and 344,342 shares sold across six transactions, resulting in net acquisitions of 1,093,195 shares. It lists total insider holdings at approximately 4 million shares and net acquisitions at 37.6% of those holdings.

Among the 10 latest individual records, nine were zero-price stock awards or a gift for which the supplied data did not include share quantities. The remaining record was a CEO sale in March 2026; these records do not by themselves establish insiders’ views on the company’s outlook.

Risks investors should monitor

• Continuing losses and declining liquidity: The cash balance fell by $32.3 million during Q2 and $93.8 million during the first half. Management’s funding outlook depends partly on anticipated revenue and future expense moderation.
• Product-mix and revenue-recognition volatility: Fanapt growth did not offset the reported HETLIOZ decline. The delayed recognition of approximately $7.0 million of HETLIOZ orders also shows how shipment timing can move revenue between quarters.
• Launch execution: Reaching the full-year revenue range requires a substantially higher second-half contribution, making the BYSANTI launch and expansion of NEREUS promotion important variables.
• Clinical and regulatory outcomes: Quimilza’s FDA review and multiple Phase III readouts are scheduled over a concentrated period. Delays or unfavorable outcomes could affect future commercial opportunities without reversing spending already incurred.

Summary

Vanda’s Q2 2026 results showed continued Fanapt prescription and revenue growth, but lower reported HETLIOZ sales and elevated launch and clinical spending produced a much wider loss and another decline in cash. The next points to monitor are the Q3 recognition of delayed HETLIOZ orders, the pace of the BYSANTI and NEREUS launches, management’s expected expense moderation, and the company’s late-2026 regulatory and clinical milestones.